Please assess the completion status of the following clinical trial:

Trial Title: Carboplatin Combined With Paclitaxel in Treating Patients With Advanced Thymoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed invasive, recurrent, or metastatic thymoma or thymic carcinoma not amenable to potentially curative therapy by surgery~* Extensive disease (distant disease, pleural disease, pulmonary with or without mediastinal disease, or recurrent progressive disease in site of prior radiotherapy)~* Advanced limited disease allowed if ineligible for primary radiotherapy or surgery~* Measurable disease~* Age 18 and over~* ECOG Performance Status 0-1~* Granulocyte count at least 1,500 cells/mm\^3~* Platelet count at least 100,000 cells/mm\^3~* Bilirubin no greater than 1.5 mg/dL~* Creatinine no greater than 2.0 mg/dL~* Concurrent corticosteroids for myasthenia gravis or other chronic conditions allowed~Exclusion Criteria:~* Acute concurrent complications such as infection or post-surgical complications~* Other prior malignancy within the past 5 years unless curatively treated with no evidence of recurrence~* Pregnant or nursing. A negative pregnancy test was required, and fertile patients must use effective contraception~* Prior chemotherapy for metastatic disease. Prior preoperative or adjuvant chemotherapy allowed if disease-free survival prior to recurrence was more than 1 year

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Paclitaxel plus Carboplatin (Type: EXPERIMENTAL): Paclitaxel 225 mg/m2 IV over 3 hours and Carboplatin AUC 6.0 IV over 30 minutes on day 1 of a 21-day cycle

Based on this trial design, predict the completion outcome and termination type (if applicable).